Exploring Glovadalen: A Promising New Treatment for Parkinson's Disease in the ATLANTIS Study

Parkinson's disease is a progressive neurological condition that affects movement control. Researchers are continually exploring new treatments to alleviate its symptoms and improve patients' quality of life. One such promising treatment under investigation is glovadalen, a medication currently undergoing clinical trials.​ What is Glovadalen? Glovadalen, also known by its developmental code name UCB-0022, is an experimental drug being developed by UCB Biopharma for the treatment of Parkinson's disease. It functions as a dopamine D1 receptor positive allosteric modulator (D1PAM), meaning it enhances the effectiveness of dopamine—a neurotransmitter crucial for movement control—without directly stimulating dopamine receptors. This mechanism aims to improve motor function in PD patients. ​ The ATLANTIS Study: Testing Glovadalen's Effectiveness To evaluate glovadalen's potential, UCB Biopharma initiated the ATLANTIS study, a Phase 2 clinical trial. This study is notable for its patient-informed design, incorporating feedback from individuals with Parkinson's to optimize study accessibility and reduce participant burden. ​ Study Design and Objectives The ATLANTIS study is a multicenter, double-blind, placebo-controlled, randomized trial involving 207 participants across 69 sites in the United States. Participants are aged between 35 and 85, have been diagnosed with Parkinson's for at least five years, and experience significant daily motor fluctuations despite stable levodopa therapy. The trial consists of several phases:​ Screening Period: A 6-week phase to assess participant eligibility.​ Titration Period: A 2-week phase where participants receive either low-dose glovadalen, high-dose glovadalen, or a placebo.​ Maintenance Period: An 8-week phase of continued treatment to evaluate sustained effects.​ Follow-Up: A 2-week safety monitoring phase post-treatment.​ The primary goal of the study is to measure the change in the average number of hours per day participants spend in the "OFF" state—times when medication is not working optimally—from the start to the end of the study. Secondary objectives include monitoring the incidence of treatment-emergent adverse events and assessing drug levels in the body. ​ Patient-Centric Approach A distinctive feature of the ATLANTIS study is its emphasis on patient engagement. UCB Biopharma established a patient council comprising patients, caregivers, and patient organizations to provide insights into study design and implementation. This collaboration aims to ensure that the trial addresses real-world concerns and enhances the participant experience. ​ Current Status and Future Outlook As of April 2025, the ATLANTIS study is ongoing, with completion expected by the end of the year. Initial results are anticipated in March 2025. These findings will shed light on glovadalen's efficacy and safety, potentially offering a new therapeutic option for individuals living with Parkinson's disease. ​ Conclusion The exploration of glovadalen represents a significant step forward in Parkinson's disease research. By enhancing dopamine signaling, glovadalen may provide relief from motor symptoms. The patient-informed approach of the ATLANTIS study underscores the importance of involving those affected by Parkinson's in the research process, aiming to develop treatments that truly meet their needs.